151 related articles for article (PubMed ID: 37466065)
1. Neuroendocrine tumor chromogranin A response following synthetic somatostatin analog (lanreotide): Early observations from an isolated duodenal neoplasm .
Sills ES; Wood SH; Tan SL; Ibach DM
Neuro Endocrinol Lett; 2023 Jul; 44(4):265-269. PubMed ID: 37466065
[TBL] [Abstract][Full Text] [Related]
2. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
3. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
[TBL] [Abstract][Full Text] [Related]
4. Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.
Bodei L; Kidd M; Modlin IM; Prasad V; Severi S; Ambrosini V; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G; Drozdov I
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1341-52. PubMed ID: 25947577
[TBL] [Abstract][Full Text] [Related]
5. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
Herrera-Martínez AD; van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Culler MD; de Herder WW; Luque RM; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2019 Jun; 26(6):585-599. PubMed ID: 30939452
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role.
Cimitan M; Buonadonna A; Cannizzaro R; Canzonieri V; Borsatti E; Ruffo R; De Apollonia L
Ann Oncol; 2003 Jul; 14(7):1135-41. PubMed ID: 12853358
[TBL] [Abstract][Full Text] [Related]
7. Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors.
Couvelard A; Pélaprat D; Dokmak S; Sauvanet A; Voisin T; Couvineau A; Ruszniewski P
Pancreas; 2017; 46(5):631-638. PubMed ID: 28375946
[TBL] [Abstract][Full Text] [Related]
8. Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe 1-Tyr 3-octreotide and chromogranin A assay in patients with neuroendocrine tumours.
Rodrigues M; Gabriel M; Heute D; Putzer D; Griesmacher A; Virgolini I
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1796-802. PubMed ID: 18425512
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
10. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
11. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor scintigraphy and chromogranin A assay in staging and follow-up of patients with well-differentiated neuroendocrine tumors.
Stokkel MP; Rietbergen DD; Korse CM; Taal BG
Nucl Med Commun; 2011 Aug; 32(8):731-7. PubMed ID: 21633314
[TBL] [Abstract][Full Text] [Related]
13. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
[TBL] [Abstract][Full Text] [Related]
14. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
[TBL] [Abstract][Full Text] [Related]
15. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract][Full Text] [Related]
16. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors.
Faiss S; Räth U; Mansmann U; Caird D; Clemens N; Riecken EO; Wiedenmann B
Digestion; 1999; 60(5):469-76. PubMed ID: 10473972
[TBL] [Abstract][Full Text] [Related]
17. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
Saif MW
Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
[TBL] [Abstract][Full Text] [Related]
18. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
Michael M; Garcia-Carbonero R; Weber MM; Lombard-Bohas C; Toumpanakis C; Hicks RJ
Oncologist; 2017 Mar; 22(3):272-285. PubMed ID: 28220021
[TBL] [Abstract][Full Text] [Related]
19. Illuminating somatostatin analog action at neuroendocrine tumor receptors.
Reubi JC; Schonbrunn A
Trends Pharmacol Sci; 2013 Dec; 34(12):676-88. PubMed ID: 24183675
[TBL] [Abstract][Full Text] [Related]
20. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature.
Vitale G; Dicitore A; Sciammarella C; Di Molfetta S; Rubino M; Faggiano A; Colao A
Endocr Relat Cancer; 2018 Jun; 25(6):R351-R364. PubMed ID: 29643113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
